Home » Topics » BioWorld Science

BioWorld Science
RSS

cis-Regulatory elements of the FOXA1 plexus as therapeutic targets in prostate cancer

Jan. 29, 2020

V-4020, a novel VEEV vaccine with increased safety and stability

Jan. 29, 2020

FDA approves first human trials of Myeliviz for PET imaging in MS

Jan. 29, 2020

First patient dosed in phase I study of SY-5609

Jan. 29, 2020

TRuE-AD2 pivotal phase III study of ruxolitinib cream meets primary endpoint

Jan. 29, 2020

Blueberry Therapeutics receives IND clearance from the FDA for BB-2603

Jan. 29, 2020

Topline data from phase III VELOS-2 study of HL-036

Jan. 29, 2020

New phase I trial studies monoclonal antibody CIS-43LS against malaria

Jan. 29, 2020

Skin-deep defense may be good enough for arboviruses

Jan. 29, 2020

Mutant TP53 affects fat metabolism

Jan. 29, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...